David Wong,
Felix and Mildred Yip Endowed Chair in Dentistry; Director for UCLA Center for Oral/Head & Neck Oncology Research,
University of California-Los Angeles
David T.W. Wong DMD, DMSc is Felix & Mildred Yip Endowed Professor, Associate Dean of Research and Director of the Oral/Head and Neck Oncology Research Center at UCLA. Dr. Wong is an active scientist in oral cancer and saliva diagnostics research. He has authored over 280 peer reviewed scientific publications. He is a fellow of the American Association for the Advancement of Sciences (AAAS), past member of the ADA Council of Scientific Affairs and the past president of American Association of Dental Research (AADR).
Saliva-Based Detection of Actionable EGFR Mutation in Lung Cancer Patients
Monday, 16 November 2015 at 10:00
Add to Calendar ▼2015-11-16 10:00:002015-11-16 11:00:00Europe/LondonSaliva-Based Detection of Actionable EGFR Mutation in Lung Cancer PatientsSELECTBIOenquiries@selectbiosciences.com
Constitutive activation of epithelial growth factor receptor (EGFR) is
prevalent in epithelial cancers, particularly in non-small-cell lung
carcinoma (NSCLC). EGFR mutation predicts sensitivity to EGFR-targeted
therapy and mutation detection is mainly based on tissue biopsy, which
is invasive, expensive and time-consuming. Non-invasive, real-time,
point-of-care, inexpensive detection and monitoring of EGFR mutations in
NSCLC patients is highly desirable. We developed a novel core
technology, Electric Field-Induced Release and Measurement (EFIRM),
relying on a multiplexible electrochemical sensor that can detect EGFR
mutations directly from body fluids. EFIRM for EGFR mutation detection
was established in vitro, and correlated with tumor size from
xenografted mice. In clinical application, we demonstrated that EFIRM
can detect EGFR mutations from saliva and serum of 22 NSCLC patients.
And finally, a blinded test was performed on saliva from 40 NSCLC
patient saliva samples. The receiver operating characteristic analysis
indicated that EFIRM detected the exon 19 deletion with an area under
the curve (AUC) of 0.94 and the L858R mutation with an AUC of 0.96. Our
data indicate that EFIRM is effective, accurate, rapid, user-friendly,
and cost effective for the detection of EGFR mutations in saliva of
NSCLC patients.
Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonHigh-Value DiagnosticsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-11-16 10:00:002015-11-16 11:00:00Europe/LondonSaliva-Based Detection of Actionable EGFR Mutation in Lung Cancer PatientsSELECTBIOenquiries@selectbiosciences.com
